SGLT2 Inhibitors Show No Significant Serious UTI Excess

This trial-level meta-analysis reassures pharmacists that SGLT2 inhibitor urinary safety differs meaningfully from the well-established genital infection risk.

SGLT2 inhibitorsempagliflozindapagliflozincanagliflozinertugliflozinbexagliflozinurinary tract infectiontype 2 diabetesheart failurechronic kidney diseasemeta-analysisdrug safety Endocrinology / Diabetes / Obesity

Background Information

SGLT2 inhibitors show no significant rise in UTI risk.

The risk of urinary tract infections (UTIs) with SGLT2 inhibitors is unclear despite their common use for type 2 diabetes, heart failure, and chronic kidney disease. SGLT2 inhibitors did not show a statistically significant increase in any UTI (RR 1.08, P = 0.060) or serious/complicated UTI (RR 0.99, P = 0.960). These results indicate no significant rise in UTIs, differentiating between lower-grade urinary events and more severe infections, unlike the known risk of genital infections. SGLT2 inhibitors do not significantly increase UTI risk, distinguishing them from risks of genital infections.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Matteucci A, Di Fusco SA, Bonanni M, Castello L, Aquilani S, Fedele S, Nardi F, Colivicchi F

Citation: Matteucci A, Di Fusco SA, Bonanni M, et al. Are SGLT2 inhibitors really associated with increased urinary tract infection risk? A trial-level meta-analysis across type 2 diabetes, heart failure, and chronic kidney disease. Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences. 2026;34(2). doi:10.1007/s40199-026-00637-7

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →